Full-Time

Senior Director Artificial Intelligence

Artificial Intelligence

Cellanome

Cellanome

51-200 employees

Automated platform for live single-cell assays

Compensation Overview

$288k - $330k/yr

+ Stock Options

San Mateo, CA, USA

In Person

On-site in Foster City, CA. Up to 5% travel may be required.

Bachelor's, Master's, PhD

Category
AI & Machine Learning (2)
,
Required Skills
TensorFlow
Neural Networks
PyTorch
Computer Vision

Get referred to Cellanome

See people who can refer or advise you

Requirements
  • PhD in Engineering, computer science, computational biology or related fields with 15 years experience; or a Master’s degree with 18 years experience; or a Bachelor’s degree with 20 years experience; or equivalent experience.
  • A minimum of 10 years of leadership experience, including hiring and mentoring junior team members.
  • Comprehensive knowledge of Deep Learning-based methodologies for image analysis is a must. The successful candidate will have extensive familiarity with object detection, instance segmentation and feature extraction models and will have demonstrated experience training and tweaking them.
  • Excellent programming skills and intimate familiarity with commonly used Deep Learning frameworks such as PyTorch, TensorFlow etc.
  • Excellent problem-solving abilities, critical thinking, and communication skills.
  • Demonstrated ability to perform the Essential Duties of the position with or without reasonable accommodations.
Responsibilities
  • Design, develop, train and productize cutting-edge Deep Learning models, particularly in the area of image processing for tasks such as image segmentation, classification, unsupervised and semi-supervised feature extraction.
  • Research and develop models for integrating paired imaging and transcriptomic data from the same cells.
  • Design and develop infrastructure for tracking model learning and performance.
  • Develop and implement a multi-year strategy for application of ML and AI-based methodologies to core aspects of the operation of our technology, and interpretation of the resulting data.
  • Identify new opportunities to deploy ML and AI-based methodologies based on conversations with internal and external stakeholders.
  • Source, hire and mentor junior team members, fostering an environment of healthy teamwork and continuous learning.
  • Work collaboratively with other software teams to integrate ML and AI-based methodologies into our broader software ecosystem.
  • Keep up with the rapidly changing AI and ML landscape to identify new opportunities.
  • Ability to work in front of a computer screen and/or perform typing for approximately 90% of a typical working day.
  • Ability to travel up to 5% of working time away from work location, may include overnight/weekend travel at times.
Desired Qualifications
  • PhD strongly preferred.
  • Experience working with biological imaging data (e.g. live cell microscopy, histopathology).
  • Experience working with foundation models for single-cell transcriptomics.

Cellanome provides an automated platform for live-cell phenotypic and functional assays that analyze single cells at scale. It runs high-throughput experiments that integrate with existing lab workflows, collecting multi-parameter data and allowing iterative testing under different conditions. The system emphasizes single-cell granularity, scalable data collection, and easy assay customization without major process changes. Its goal is to help life sciences, medical research, pharmaceutical, and biotech teams gain deeper cellular insights to accelerate discovery through a platform-as-a-service model.

Company Size

51-200

Company Stage

Series C

Total Funding

$276.9M

Headquarters

Foster City, California

Founded

2020

Get referred to Cellanome

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Psomagen added the R3200 on March 26, 2026, validating external demand.
  • Cellanome showcased live-cell analysis marrying imaging and sequencing at AGBT 2026.
  • Cellanome raised $75.9 million on June 22, 2026, extending runway.

What critics are saying

  • 10x Genomics and other single-cell vendors already dominate adjacent workflows.
  • Cellanome still lacks proof of broad customer adoption beyond Psomagen and conferences.
  • If 2026 spending misses hardware sales, the platform becomes an expensive science project.

What makes Cellanome unique

  • Cellanome links longitudinal live-cell imaging to single-cell transcriptomics from the same cells.
  • Its CellCage micro-3D-printed enclosures isolate cells while drugs and antibodies flow.
  • R3200 captures morphology, phenotype, and RNA on identical live cells.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Stock Options

401(k) Retirement Plan

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

58%

2 year growth

0%
U.S. Securities and Exchange Commission
Jul 17th, 2026
EDGAR Filing Documents for 0000905148-26-003005

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231Type: D | Act: 33 | File No.: 021-588010 | Film No.: 261104659

Intelligence360 News
Jul 17th, 2026
Cellanome files to raise $75.9M for live-cell imaging and single-cell transcriptomics platform

Cellanome has filed a notice with the US Securities and Exchange Commission to raise up to $75.9 million in new funding. The filing was made under Regulation D of the Securities Act of 1933, which allows companies to sell securities without full registration. The company develops technologies that combine longitudinal live-cell imaging with single-cell transcriptomics from the same cells. This approach enables scientists to capture cellular dynamics over time and connect cellular behaviour with molecular state. Researchers can access Cellanome's technology by implementing its R3200 platform in their laboratories, using its assay services, or collaborating with the company's scientists on new applications.

The Business Journals
Jan 30th, 2024
Peninsula startup with Illumina roots lands $150 million to peer deeper into cells

A Peninsula startup launched by top former Illumina execs raises $150 million to help researchers see what happens when cells dance with each other.

The Business Journals
Dec 8th, 2021
Former Illumina execs, Grail co-founder raise $21M for biotech startup

Biotech A-listers have come together to launch a new venture. What's it targeting? They're not saying.